Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL

Jonathan W. Friedberg, Andres Forero-Torres, Rodolfo E. Bordoni, Vivian J.M. Cline, Dipti Patel Donnelly, Patrick J. Flynn, Gregg Olsen, Robert Chen, Abraham Fong, Yinghui Wang and Christopher A. Yasenchak

Article Information


Print ISSN 
Online ISSN 
  • Submitted June 13, 2017
  • Accepted October 3, 2017
  • Published online October 16, 2017.

Article Versions

  • Jonathan W. Friedberg, 1 University of Rochester Wilmot Cancer Institute, Rochester, NY, United States;
  • Andres Forero-Torres, 2 University of Alabama at Birmingham, Birmingham, AL, United States;
  • Rodolfo E. Bordoni, 3 Georgia Cancer Specialists, Marietta, GA, United States;
  • Vivian J.M. Cline, 4 Texas Oncology-Round Rock Seton Williamson, Round Rock, TX, United States;
  • Dipti Patel Donnelly, 5 Virginia Cancer Specialists, Fairfax, VA, United States;
  • Patrick J. Flynn, 6 Minnesota Oncology, Woodbury, MN, United States;
  • Gregg Olsen, 7 Providence Saint Joseph Medical Center, Burbank, CA, United States;
  • Robert Chen, 8 City of Hope Medical Center, Duarte, CA, United States;
  • Abraham Fong, 9 Seattle Genetics, Inc., Bothell, WA, United States;
  • Yinghui Wang, 9 Seattle Genetics, Inc., Bothell, WA, United States;
  • Christopher A. Yasenchak, 10 Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR, United States Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output